Related Experiment Video
Updated: Feb 25, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies
Jamie Garside1, Nollaig Healy2, Hervé Besson3
1Janssen EMEA HEMAR, High Wycombe, UK.
Aim:
PHEDRA (Platform for Haematology in EMEA: Data for Real World Analysis) is a unique, noninterventional project based on secondary data collection from real-world (RW) patient-level (health record) databases to understand treatment patterns in hematological malignancies. It compares ibrutinib's effectiveness with alternative treatments using RW data (RWD) and randomized clinical trials data.
Materials & Methods:
RWD are cleaned, validated, harmonized into a Common Data Model, and analyzed statistically alongside randomized clinical trial data. Treatment outcomes include overall and progression-free survival.
Results:
To date, RWD (four databases) are available for 2840 patients in three indications, collected between 1990 and 2017.
Conclusion:
PHEDRA is an innovative approach to generate evidence to inform optimal treatment decisions in RW settings.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

